Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Temporary Alleviation of MAPK by Arbutin Alleviates Oxidative Damage in the Retina and ARPE-19 Cells

ABSTRACT: Temporary Alleviation of MAPK by Arbutin Alleviates Oxidative Damage in the Retina and ARPE-19 Cells

PROVIDER: PRJNA1104996 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28819642_1.fastq.gz	Fastqsanger.gz
	SRR28819642_2.fastq.gz	Fastqsanger.gz
	SRR28819643_1.fastq.gz	Fastqsanger.gz
	SRR28819643_2.fastq.gz	Fastqsanger.gz
	SRR28819644_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Temporary Alleviation of MAPK by Arbutin Alleviates Oxidative Damage in the Retina and ARPE-19 Cells

Project description:Dry age-related macular degeneration (AMD) is one of the main diseases that causes blindness in humans and the number of cases is increasing every year, but effective treatments are not available, arbutin (ARB) has been reported to have antioxidant, anti-inflammatory, and anti-aging effects in other age-related diseases. However, whether it can help treat dry AMD remains unknown.in this study, we found 10-100 μM ARB concentration-dependently reversed the H2O2-induced viability decline in HRPECs, and ARB inhibited H2O2-induced HRPEC ROS production and apoptosis by changing the expression of antioxidant and apoptosis-related genes and proteins. Transcriptome sequencing and western blotting showed that ARB reduced ERK1/2 and P-38 phosphorylation to prevent H2O2-induced oxidation damage. We concluded ARB reversed the H2O2-induced decline in HRPEC activity, which was related to inhibition of ROS production and apoptosis. The ERK1/2 and P38 MAPK signaling pathways may have mediated this process.

2024-05-05 | GSE265933 | GEO

Temporary alleviation of MAPK by arbutin alleviates oxidative damage in the retina and ARPE-19 cells.

Project description:Dry age-related macular degeneration (AMD) is one of the main diseases that causes blindness in humans, and the number of cases is increasing yearly. However, effective treatments are unavailable, and arbutin (ARB) has been reported to have antioxidant, anti-inflammatory, and anti-aging effects in other age-related diseases. However, whether ARB can be used to treat dry AMD remains unknown. To explore the therapeutic potential and molecular mechanism of arbutin in the treatment of dry AMD. MTT assays, reactive oxygen species (ROS) production assays, flow cytometry assays, qPCR and western blotting were used to assess the impact of ARB on human RPECs induced by H2O2. A transcriptome sequencing assay was used to further explore how ARB acts on human RPECs treated with H2O2. Hematoxylin and eosin (H&E) staining and total antioxidant capacity (T-AOC) assays were used to observe the impact of ARB on mouse retina induced by sodium iodate. ARB counteracted the H2O2-induced reduction in human RPECs viability, ARB reversed H2O2-induced cellular ROS production by increasing the expression of antioxidant-related genes and proteins, ARB also reversed H2O2-induced cell apoptosis by altering the expression of apoptosis-related genes and proteins. Transcriptome sequencing and western blotting showed that ARB reduced ERK1/2 and P-38 phosphorylation to prevent H2O2-induced oxidation damage. The in vivo experiments demonstrated that ARB protected against retinal morphology injury in mice, increased serum T-AOC levels and increased antioxidant oxidase gene expression levels in the mouse retina induced by sodium iodate. We concluded that ARB reversed the H2O2-induced decrease in human RPECs viability through the inhibition of ROS production and apoptosis. The ERK1/2 and P38 MAPK signaling pathways may mediate this process. ARB maintained retinal morphology, increased serum T-AOC level and improved the expression of antioxidant oxidase genes in mice.

| S-EPMC11234033 | biostudies-literature

Temporary Upregulation of Nrf2 by Naringenin Alleviates Oxidative Damage in the Retina and ARPE-19 Cells.

Project description:Dry age-related macular degeneration (dAMD) is a chronic degenerative ophthalmopathy that leads to serious burden of visual impairment. Antioxidation in retinal pigment epithelium (RPE) cells is considered as a potential treatment for dAMD. Our previous studies have showed that naringenin (NAR) protects RPE cells from oxidative damage partly through SIRT1-mediated antioxidation. In this study, we tested the hypothesis that the Nrf2 signaling is another protective mechanism of NAR on dAMD. NaIO3-induced mouse retinopathy and ARPE-19 cell injury models were established. Immunochemical staining, immunofluorescence, and western blotting were performed to detect the protein expressions of Nrf2 and HO-1. In addition, ML385 (activity inhibitor of Nrf2) and zinc protoporphyrin (ZnPP, activity inhibitor of HO-1) were applied to explore the effect of NaIO3 or NAR. The results showed that NAR increased the protein expressions of Nrf2 and HO-1 in the retinas in mice exposed to NaIO3 at the early stage. NAR treatment also resulted in a stronger activation of Nrf2 at the early stage in NaIO3-treated ARPE-19 cells. Moreover, inhibition of HO-1 by ZnPP weakened the cytoprotective effect of NAR. The constitutive accumulation and activation of Nrf2 induced by NaIO3 led to the death of RPE cells. However, NAR decreased the protein expressions of Nrf2 and HO-1 towards normal level in the mouse retinas and ARPE-19 cells exposed to NaIO3 at the late stage. Our findings indicate that NAR protects RPE cells from oxidative damage via activating the Nrf2 signaling pathway.

| S-EPMC8612781 | biostudies-literature

ARPE-19_adriamycin_gene_expression

Project description:This study compared the gene expression change of ARPE-19 cells before and after adriamycin treatment ARPE-19 cells were treated with 1Î¼M adriamycin for 24 h compared with control

2016-03-01 | E-GEOD-78765 | biostudies-arrayexpress

Temporary Name

Project description:Temporary Short Descriptive Study Title

| PRJEB55127 | ENA

ARPE-19_adriamycin_gene_expression

Project description:This study compared the gene expression change of ARPE-19 cells before and after adriamycin treatment

2016-03-01 | GSE78765 | GEO

ARPE-19 adriamycin gene expression II

Project description:This study compared the gene expression change of ARPE-19 cells before and after adriamycin treatment

2017-10-06 | GSE104662 | GEO

MAPK

Project description:MAPK

| PRJNA1054526 | ENA

Gene expression signitures in ARPE-19 cells treated with or without TGF-β1

Project description:To identify the dysregulated lncRNA and mRNA expression in ARPE-19 cells underwent EMT, we established a TGF-β1 induced EMT model of ARPE-19 cells. ARPE-19 cells were treated with or without 10 ng/ml TGF-β1 for 48 h. Total RNA are extracted and subjected to microarray assay (Arraystar Human LncRNA Microarray V3.0)

2021-08-11 | GSE105053 | GEO

Expression Data from DMSO or SRPIN803 treated ARPE-19 cells

Project description:We used microarrays to evaluate the effect of SRPIN803 on gene expression in ARPE-19 cells. ARPE-19 cells were treated with SRPIN803 (10 uM) or the negative control (0.1% DMSO) for 4 hours for Total RNA isolation and hybridization on Microarray.

2015-06-17 | E-GEOD-62947 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data